ARQT icon

Arcutis Biotherapeutics
ARQT

Upgrade to unlock
Buy
Hold
Sell

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$32
24% upside
High target

3 analyst ratings

positive
1  neutral
33%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
Mizuho
Mizuho
Uy Ear
50% 1-yr ARQT win rate
28 Nov ‘25 1 month ago
Goldman Sachs
Goldman Sachs
Richard Law
30 Oct ‘25 2 months ago
Needham
Needham
Serge Belanger
83% 1-yr ARQT win rate
28 Oct ‘25 2 months ago